Methods and composition for the prediction of the activity of enzastaurin
US11421280B2 · kind B2 · utility
0Cited by
2References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 31, 2017 |
| Grant date | Aug 23, 2022 |
| Priority date | — |
| Expiry date | Feb 4, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/156
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention describes biomarkers that have been discovered to correlate with varied individual responses (e.g., efficacy, adverse effect, and other end points) to enzastaurin, in treating diseases such as, DLBCL, GBM, and other cancer types. The newly discovered biomarkers and others in linkage disequilibrium with them can be used in companion diagnostic tests which can help to predict drug responses and apply drugs only to those who will be benefited, or exclude those who might not be beneficial, by the treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.